What Does a Thickened Endometrium After Menopause Mean?

A thickened endometrium after menopause is usually a benign finding, but it gets attention because the uterine lining is supposed to thin out once estrogen levels drop. In most postmenopausal women, the endometrial stripe on ultrasound measures around 3 mm or less. When it measures more than that, clinicians have to decide whether the thickening reflects something harmless, like a small polyp or lingering hormonal influence, or something that warrants a closer look. The answer depends heavily on whether you have symptoms, how thick the lining actually is, and what other risk factors you carry.

What Counts as Normal After Menopause

During your reproductive years, the endometrium thickens and sheds with each menstrual cycle, routinely reaching 10 mm or more before a period. After menopause, that cycle stops, and the lining gradually thins. A study tracking endometrial thickness over time found that during the first five years after menopause, the average thickness was about 2.3 mm, then settled around 1.8 mm and stayed relatively stable for years afterward.¹ A large meta-analysis pooling data from over 11,000 asymptomatic postmenopausal women estimated the mean endometrial thickness at about 2.9 mm.²

So when a radiologist reports that your endometrium is “thickened,” they generally mean it exceeds somewhere around 4 to 5 mm. There is no single universal cutoff that all practitioners agree on, though. The threshold that triggers further investigation shifts depending on whether you are experiencing postmenopausal bleeding or whether the finding was incidental, picked up during an ultrasound done for an unrelated reason.

Bleeding Changes Everything

The clinical stakes are different depending on whether you walked into the office because of spotting or whether a routine scan happened to show a thick lining. In women with postmenopausal bleeding who turned out to have endometrial cancer, the average endometrial thickness was about 16 mm. In women with the same bleeding but no cancer, the average was only about 4 mm.³ That gap is wide enough to make thickness a useful screening tool when bleeding is present. For women with bleeding, most guidelines use a 4 or 5 mm cutoff: below that, endometrial cancer is unlikely enough that many clinicians feel comfortable monitoring rather than biopsying.

The picture is murkier for women without symptoms. In one study of asymptomatic postmenopausal women whose thickened endometrium was discovered by chance, the overall rate of malignancy was about 3.7%. But when thickness exceeded 10 mm, that rate jumped to about 16%.⁴ Another cohort study of asymptomatic women with thickened endometrium concluded that the risk of precancerous changes and malignancy was minimal overall but still warranted long-term follow-up, especially when Doppler ultrasound showed blood flow signals within the endometrium.⁵

Common Benign Causes

Most of the time, a thick endometrial stripe in a postmenopausal woman is not cancer. Endometrial polyps are among the most frequent culprits. These are small growths that protrude from the uterine lining. They are overwhelmingly benign and occur in both reproductive-age and postmenopausal women.⁶ When researchers looked at polyps removed from both premenopausal and postmenopausal women, only about 2% in each group harbored malignancy.⁷ Polyps can make the endometrium look thicker than it really is on ultrasound, because the measurement includes the polyp’s height.

Fluid collecting inside the uterus can also create a misleading impression. In postmenopausal women with cervical stenosis, where the cervix has narrowed to the point that fluid cannot drain, intrauterine fluid can accumulate. A study of 82 such women found that 84% had atrophic (thinned, normal) endometrium despite the concerning ultrasound appearance. Of those whose endometrial thickness measured 8 mm or more, polyps were present in 93% of cases, and no cancers were found in the entire group.⁸ That said, fluid distending the uterine cavity is worth investigating, because older literature documented that a distended uterine cavity in a postmenopausal woman sometimes pointed to cancer involving the uterus.⁹ Context matters: isolated fluid with a thin endometrium is far less worrisome than fluid alongside a thickened, irregular lining.

Hormones and Medications That Thicken the Lining

If you are on hormone replacement therapy (HRT), a thicker endometrium is expected and does not carry the same implications as the same measurement in someone not taking hormones. In women on sequential HRT (estrogen for part of the cycle, then a progestin), average endometrial thickness was around 8 mm, compared to about 5 mm in controls not on hormones.¹⁰ Combined continuous HRT tends to produce a thinner stripe than sequential regimens, generally around 5 mm, while unopposed estrogen (estrogen without a progestin) can push the lining anywhere from 3 to 15 mm.¹¹ This wide range with unopposed estrogen is one reason it is rarely prescribed alone to women who still have a uterus; without a progestin to counterbalance it, estrogen steadily stimulates the lining.

Tamoxifen, a drug widely used in breast cancer treatment, is another major cause of endometrial thickening. Despite being an estrogen blocker in breast tissue, tamoxifen acts as a partial estrogen agonist in the uterus. This creates a paradox: the drug can make the endometrium appear substantially thickened on ultrasound, yet the underlying tissue is often atrophic. Researchers describe this as “tamoxifen mucosa” or endometrial cystic atrophy, a pattern of thickening driven by tamoxifen’s complex mix of estrogen-like and anti-estrogen effects on the endometrium.¹² For clinicians, this makes evaluating tamoxifen users tricky, since the usual thickness cutoffs do not apply the same way. Biopsy decisions in these patients often rely more on symptoms (bleeding) and less on thickness measurements alone.

Obesity and Body Weight

Body weight has a direct, independent effect on endometrial thickness after menopause. Even after controlling for other variables, researchers found that endometrial thickness was significantly greater in obese postmenopausal women regardless of whether they had high blood pressure.¹³ The mechanism is straightforward: after menopause, the ovaries stop producing significant estrogen, but fat tissue continues converting other hormones into estrogen through a process called aromatization. The more fat tissue, the more estrogen is produced, and the more the endometrium is stimulated to grow.¹⁴

This is not just an academic observation. When researchers followed up on women whose initial biopsies showed only limited benign tissue despite a persistently thick endometrium, those who eventually turned out to have atypical hyperplasia or malignancy on repeat biopsy were more likely to have a higher body mass index.¹⁵ Obesity is one of the strongest modifiable risk factors for endometrial cancer, and a persistently thickened endometrium in an obese postmenopausal woman deserves closer attention than the same measurement in a lean one.

When Thickening Points to Something Serious

Endometrial hyperplasia, an overgrowth of the uterine lining that can precede cancer, is an intermediate category between normal and malignant. The kind without atypical cells has a low progression risk: about 5% over 20 years. But atypical hyperplasia is a different story, with a cumulative cancer progression risk of roughly 28% over the same timeframe.¹⁶ Atypical hyperplasia is treated aggressively, often with hysterectomy, because the long-term risk is high enough that watchful waiting becomes a gamble.

When endometrial cancer is present, the thickness measurements tend to be dramatically elevated. In one study of postmenopausal women with confirmed endometrial cancer, the most common subtype (endometrioid carcinoma) had an average thickness of about 18 mm. Rarer, more aggressive subtypes like carcinosarcoma averaged even higher, around 28 mm.¹⁷ These numbers are far above what benign conditions typically produce, but there is overlap in the middle range, which is why thickness alone can never be the final word.

How Clinicians Decide Whether to Biopsy

The UK Collaborative Trial of Ovarian Cancer Screening, a large screening study, found that using a 5 mm cutoff gave a sensitivity of about 80% and specificity of about 86% for detecting endometrial cancer or its immediate precursor. Raising the cutoff to 10 mm improved specificity to about 97%, but sensitivity dropped to around 54%, meaning nearly half of actual cancers would be missed.¹⁸ A more recent meta-analysis focused on asymptomatic women confirmed this tension: lower cutoffs catch more cancers but trigger many unnecessary biopsies, while higher cutoffs miss fewer healthy women but let more cancers slip through.¹⁹

For asymptomatic women, a recent recommendation suggests that hysteroscopy with directed biopsy is reasonable when endometrial thickness is 8 mm or above. For those with thickness between 4 and 8 mm, the decision should be individualized based on risk factors and whether Doppler ultrasound shows blood flow within the endometrium.²⁰ In practice, this means that two women with the same thickness measurement might get very different recommendations. A woman at 6 mm who is lean, has no bleeding, and has no family history of uterine cancer might be monitored with a repeat ultrasound. A woman at 6 mm who is obese, diabetic, or has a first-degree relative with endometrial cancer might be offered a biopsy right away.

What Biopsy Options Look Like

When a biopsy is indicated, the most common first step is a Pipelle biopsy, an office-based procedure using a thin, flexible suction catheter inserted through the cervix. It takes minutes, requires no anesthesia in most cases, and is highly accurate for detecting endometrial cancer: one meta-analysis estimated that out of 100 women with cancer, the Pipelle would correctly identify about 78, while correctly classifying 99 out of 100 women without cancer.²¹ Another study reported even higher numbers, with sensitivity around 89% and specificity at 100% for cancer detection, though it noted that about a quarter of samples were inadequate for diagnosis.²²

That inadequate-sample rate is worth knowing about. The Pipelle is a “blind” procedure, meaning the clinician cannot see where the catheter is sampling. It can miss focal lesions like polyps or small areas of cancer. Research on biopsy tissue found that a minimum tissue surface area of about 35 square millimeters was needed for reliable diagnosis.²³ When a Pipelle comes back with scant tissue or inconclusive results in a woman with a persistently thick endometrium, the next step is usually hysteroscopy, where a thin camera is inserted into the uterus to directly visualize the lining and take targeted biopsies of anything suspicious.²⁴ Hysteroscopy is particularly useful for polyps and other focal abnormalities that a Pipelle might miss.²⁵

One study tracking what happened when women had an initial biopsy that returned only limited benign surface tissue found that 57% received no follow-up at all, largely because the word “benign” on the report was reassuring. Among the subset who did get a repeat evaluation, 7% were eventually diagnosed with atypical hyperplasia or malignancy.²⁶ The takeaway: a “benign” biopsy that only yielded a small amount of surface tissue is not necessarily the all-clear, especially if the endometrium remains thick on follow-up imaging.

Racial Disparities in Ultrasound Accuracy

A finding that deserves wider awareness is that transvaginal ultrasound does not perform equally well across all populations. A study published in JAMA Network Open found that Black women had significantly lower rates of adequate endometrial visualization compared to White women, roughly 76% versus 89%. The accuracy of the ultrasound was also slightly lower in Black women. Crucially, these differences disappeared once women with uterine fibroids were excluded from the analysis.²⁷ Since fibroids are far more common in Black women, this represents a real clinical gap: the primary screening tool is less reliable in a population that already faces higher rates of aggressive endometrial cancer subtypes.

Separate research found that when applying the standard 5 mm thickness cutoff to Black patients with endometrial cancer, about 11% of cancers would be classified as normal (a false negative). Lowering the cutoff to 3 mm reduced that miss rate to roughly 4%.²⁸ This raises the question of whether the standard thickness thresholds, which were largely derived from majority-White study populations, adequately serve everyone. It is an active area of research, and some clinicians are beginning to advocate for lower biopsy thresholds or earlier hysteroscopy in patients where the ultrasound view is suboptimal.

Hereditary Risk and the Limits of Thickness Screening

Women with Lynch syndrome, a hereditary condition that sharply increases the risk of several cancers including endometrial cancer, represent a special case. You might assume that ultrasound monitoring of endometrial thickness would be a good screening strategy in this high-risk group, but studies evaluating that approach found it had a high false-positive rate and lacked real screening efficacy.²⁹ Lynch-associated endometrial cancers can develop in a lining that is not particularly thick, so thickness-based screening misses too many cases. Current guidance for Lynch syndrome carriers leans more toward regular endometrial biopsies or, in many cases, prophylactic hysterectomy after childbearing is complete.

Artificial Intelligence and Liquid Biopsy on the Horizon

Researchers are working on tools that could improve how thickened endometrium is evaluated. Machine learning models trained on ultrasound images have shown promising accuracy for distinguishing cancerous from non-cancerous endometrium. One model analyzing ultrasound features of the endometrium achieved an area under the curve of about 0.89, with sensitivity and specificity both in the low-to-mid 80s, and the performance held up when tested on an external dataset from a different hospital.³⁰ Another AI model analyzing texture and shape features of the endometrium on ultrasound reached similar accuracy levels.³¹ These tools are not yet in routine clinical use, but they could eventually help radiologists flag high-risk endometria before a biopsy is even performed.

On a completely different front, researchers are exploring whether endometrial cancer can be detected through blood or urine samples. Pilot studies have identified cancer-related biomarkers, including specific micro-RNA signatures, in urine-derived exosomes from women with endometrial cancer.³² The idea of a simple urine test that could distinguish worrisome thickening from harmless thickening is compelling, but this work is in early stages.³³ For now, the ultrasound-and-biopsy pathway remains the standard approach, with these newer technologies potentially years from routine practice.